Parkinsons Disease (PD)
Conditions
Keywords
tremor-dominant Parkinson's disease, directional deep brain stimulation, posterior subthalamic area, subthalamic nucleus
Brief summary
The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) using directional lead for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.
Detailed description
This single-center trial utilizes directional deep brain stimulation (DBS) current-steering technology to compare the clinical efficacy and tolerability of the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) for the treatment of tremor-dominant Parkinson's disease (TD-PD) within the same subject. The study is optimized into a two-phase framework to maximize patient safety and protocol compliance: Phase 1: Two-month post-implantation, acute mapping is conducted to define the therapeutic window for PSA and STN configurations in a blinded randomized order. If a configuration induces immediate, unmanageable adverse events before reaching efficacy, it is classified as "intolerant" and excluded from that participant's subsequent chronic phase. Phase 2 (Chronic Crossover): Participants with tolerated configurations are entered into a chronic randomized phase with a blinded sequence of 2-month PSA or STN chronic stimulation. Following the core two-arm crossover, all eligible patients transition into an open-label, exploratory sequential add-on phase of 2-month with combined PSA+STN stimulation to evaluate potential synergistic benefits. All participants will then be followed-up up to 12 months after surgery.
Interventions
active directional DBS with optimal stimulating parameters
Sponsors
Ruijin Hospital
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of idiopathic Parkinson's disease * tremor-dominant subtype in the off-medication condition * modified Hoehn-Yahr scale of 2 to 4 in the off-medication condition * receiving regular anti-parkinsonian drugs for more than 6 weeks * good compliance and written informed consent provided
Exclusion criteria
* Atypical parkinsonism * History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery * Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent * Presence of anatomical abnormalities in the target region * Clinically significant medical history that would increase pre-/post-operative complications * Other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III tremor subscore Between PSA and STN Stimulation in the chronic randomized phase | Baseline (pre-operation, OFF-medication) and the end of each 2-month stimulation period (Month 4 and Month 6) | The tremor subscore is derived from the sum of items 3.15 to 3.18 of the MDS-UPDRS-III. This measure directly compares the within-subject efficacy of directional PSA stimulation versus directional STN stimulation in the chronic cross-over phase. Lower scores indicate greater tremor suppression. |
Secondary
| Measure | Time frame |
|---|---|
| Change from Baseline in Fahn-Tolosa-Marin Clinical Rating Scale Between PSA and STN Stimulation in the chronic randomized phase | Baseline (pre-operation, OFF-medication) and the end of each 2-month stimulation period (Month 4 and Month 6) |
| Change from Baseline in Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III total score Between PSA and STN Stimulation in the chronic randomized phase | Baseline (pre-operation, OFF-medication) and the end of each 2-month stimulation period (Month 4 and Month 6) |
| Change from Baseline in Berg Balance Scale score Between PSA and STN Stimulation in the chronic randomized phase | Baseline (pre-operation, OFF-medication) and the end of each 2-month stimulation period (Month 4 and Month 6) |
| Change from Baseline in 39-item Parkinsons disease questionnaire Between PSA and STN Stimulation in the chronic randomized phase | Baseline (pre-operation) and the end of each 2-month stimulation period (Month 4 and Month 6) |
| Proportion of Participants with Acute Phase Intolerance to Single-Target Stimulation | Up to 2 months after sugery |
| Adverse events | Up to 12 months after surgery |
Countries
China
Contacts
CONTACTDianyou Li, MD, PhD
Outcome results
None listed